The National Physicians Alliance is calling on doctors to push back on Big Pharma’s marketing machine by just saying “no” to branded tchotchkes, drug samples and sales rep pitches. Launched Tuesday, NPA’s “Unbranded Doctor” campaign urges docs to join a n

Health Care for All of Massachusetts is one of the most innovative grassroots state health care advocacy organizations in the country, and has always been a core member of the Prescription Access Litigation coalition. Health Care for All has been a plai

CalPIRG, a member of Prescription Access Litigation's coalition, released a new report last week, titled "Playing By Their Own Rules: An Analysis of Drug Company Gifts to Doctors". As CALPIRG's announcement describes: CALPIRG released a new analysis tod

PostScript was delighted to discover DTC-In-Perspective, a blog by the CEO of the company of the same name. DTC is one of those publishing, conference/training, and consulting companies that specializes in soaking pharma for pricey analysis of its own beh

It’s a week of catch up at PostScript – here's a little link-love before the weekend hits: A great opinion column appeared in yesterday's Eugene Register-Guard. The author Gail Hacker M.D., medical director at Lane Community College Health Clinic, does an

We recently posted an item discussing a New York Times article about Genentech's drug Cerezyme . One reader posted a comment on that item, and her story is so compelling that we asked her if we could post it as a stand-alone blog entry. She agreed. Jes

Shahram Ahari, a former Eli Lilly sales rep, is in Boston this week talking to medical students at Tufts, Harvard, and Mass General Hospital about how reps make the sale to physicians -- and how the future docs can resist the pitch.   He speaks here to Ji

Yesterday, the Wall Street Journal Health Blog talked with JAMA editor-in-chief Cathy D’Angelis about this editorial, which breathed a big sigh of peer-review relief at a judge’s decision to stop Pfizer from getting its hands on some confidential journal

Yesterday we blogged here ("Why Drug Lawsuits are Necessary: FDA “isn’t capable of policing” drug safety, says Alaska Judge") about Zyprexa lawsuits, particularly the state of Alaska's (seeking to recoup the cost of treating Medicaid patients who took Zyp